Fouremm ... appreciate you recounting and sharing that conversation with Don. I gotta believe Don (BoD) will not let apabetalone (and certainly not RVX) go for less than $6-8b minimum. They may have to hang onto it for a while, and gain a few more milestones, but I think they realize they have a potential $10b company and class of drugs, ... and if it takes more time, and a development partnership, to further bake the cake then so be it.

Right now, the retail market says RVX is a sub $300m company, ... but it looks more like a $5-10b (+) company down the road with a few more likely and imminent milestones, considering addressable indications/markets, and bringing an entire new class of medicine to the forefront.

Yeah, I can see an EV of $5b today ... and a possibility of $8-10b if they want to maneuver and wait it out for max value, including interim development partnering deals for a few more years potentially?